GLP-1 Receptor Agonists Demonstrate Broad Anti-Cancer Potential

Glucagon-like peptide-1 receptor agonists may enhance several aspects of cancer treatment, according to five real-world studies that will be presented. The new research assesses patient survival rates, metastatic progression across seven tumor types, and breast cancer prevention. As a result, oncology teams may broaden their clinical understanding of medications such as dulaglutide, liraglutide, and semaglutide. The research also examines the results for patients on certain inhibitor-based regimens and immune checkpoint inhibitors.

The prevention of cancer, specifically breast cancer, is the subject of two of the five abstracts. GLP-1 receptor agonists were found to reduce the incidence of breast cancer in a real-world study including more than 100,000 overweight women. The effectiveness and safety of these medicines for primary prevention in high-risk women were assessed in a different preventive-focused trial. In light of this, the metabolic and anti-inflammatory mechanisms of GLP-1 receptor agonists may drive this preventive signal.

GLP-1 receptor agonists and DPP-4 inhibitors were examined in a large propensity-matched analysis involving over 12,000 patients. The study assessed patients with seven obesity-related malignancies in stages I, II, or III. Patients on GLP-1 medications had a 38–50% lower chance of progression for four forms of cancer. For lung cancer, 10% of the GLP-1 group experienced metastatic progression, compared to 22% of the DPP-4 group.

In the GLP-1 cohort, colorectal cancer progression decreased to 13% from 22% for DPP-4 inhibitors. The GLP-1 cohort did not exhibit a rise in pancreatitis, and adverse event rates were comparable across groups. High receptor expression also reduced overall mortality, according to a different examination of tumor data from a national atlas. This expression was linked to a 45% lower risk of breast cancer and a 33% lower risk of overall mortality.

Concurrent GLP-1 exposure significantly reduced all-cause mortality in a matched group of more than 2,900 diabetic patients. Additionally, during the research period, the combination decreased hospitalization rates and the number of composite immune-related adverse events. Therefore, the data clearly shows that patients who use both medicines at the same time have a higher chance of survival.

However, two ocular safety signals about the development of diabetic retinopathy and optic neuropathy need careful clinical consideration. In the GLP-1 cohort, these symptoms were more common. As a result, proactive ophthalmologic screening should be part of standard procedures for oncology teams caring for these patients. Early detection of these visual problems during treatment is another benefit of structured symptom reporting for clinicians.

The use of GLP-1 receptor agonists, particularly in patients with metastatic breast cancer, was the subject of a final analysis. These patients underwent endocrine therapy in addition to regimens based on cyclin-dependent kinase 4/6 inhibitors. According to preliminary evidence, a 30% decrease in mortality is associated with the addition of a GLP-1 medication to this regimen. Consequently, medication reconciliation gains a clinically significant dimension from knowledge of these possible co-benefits.